Extraperitoneal laparoscopic radical prostatectomy
10.3760/cma.j.issn.1000-6702.2009.01.018
- VernacularTitle:经腹膜外途径腹腔镜下前列腺癌根治术
- Author:
Gang ZHU
;
Shengcai ZHU
;
Ming LIU
;
Yaoguang ZHANG
;
Bin JIN
;
Ben WAN
;
Jianye WANG
- Publication Type:Journal Article
- Keywords:
Laparoscopes;
Prostatic neoplasms;
Carcinoma;
Radical prostatectomy
- From:
Chinese Journal of Urology
2009;30(1):51-54
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficiency and safety of extraperitoneal laparoscopic radi-cal prostatectomy for the treatment of localized prostate cancer. Methods Fifteen localized prostate cancer patients were treated with extraperitoneal laparoscopic radical prostatectomy. The mean pre-op-erative PSA was 8.1 ng/ml and prostate biopsy pathological Gleason score was 5.7±1.3. The Beijing Hospital Technique characterized by cutting directly into linea alba abdominis was used to establish the extraperitoneal space. Harmonic scrapple was used in dissection and haemostasis during the proce-dure. This technique was evaluated in respects of operating time, estimated blood loss, complications during surgery, postoperative complications, post-operative pain score (NRS), catheterization time, length of hospital stay, pathological results and post-operative PSA. Results All the surgeries had been completed successfully except 1 case converted to open surgery. The average operation time was (316±74)min, the average estimated blood loss was (4084±362)m1. There were 5 cases accepted blood transfusion. No rectal or ureteral injury happened during operation. The NRS at post-operative day 1 and day 2 were 2.3 and 1.4. The average length of hospital stay was (19.5±4.9)d. The cathe-terization time was (14.1±2.9)d. There were 2 cases (13%) with positive surgical margins. No case was found having lymph node metastasis. During the 1-12 month follow up, 10 cases (67%) were continence. PSA in 12 cases was lower than 0.2 ng/ml. Conclusion Extraperitoneal laparoscopic radical prostatectomy is feasible and safe in the treatment of localized prostate cancer.
